United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $986,220.00 in Stock

United Therapeutics Co. (NASDAQ:UTHRGet Free Report) CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $273.95, for a total transaction of $986,220.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $35,613.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

United Therapeutics Stock Up 2.0 %

Shares of UTHR stock opened at $287.59 on Friday. The stock has a 50 day moving average of $257.25 and a 200 day moving average of $238.25. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04. The stock has a market cap of $12.76 billion, a P/E ratio of 13.60, a P/E/G ratio of 4.10 and a beta of 0.49. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $288.35.

United Therapeutics (NASDAQ:UTHRGet Free Report) last posted its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, beating analysts’ consensus estimates of $5.63 by $0.54. The business had revenue of $677.70 million during the quarter, compared to analysts’ expectations of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The business’s revenue was up 33.7% compared to the same quarter last year. During the same period in the previous year, the business earned $4.86 earnings per share. As a group, sell-side analysts expect that United Therapeutics Co. will post 24.61 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on UTHR. Wells Fargo & Company lifted their target price on shares of United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a research note on Wednesday. The Goldman Sachs Group increased their price target on United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Wedbush reissued an “outperform” rating and issued a $308.00 price objective on shares of United Therapeutics in a report on Thursday, February 22nd. JPMorgan Chase & Co. raised their target price on United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a report on Tuesday, May 21st. Finally, HC Wainwright reiterated a “buy” rating and set a $300.00 price target on shares of United Therapeutics in a research report on Thursday, May 2nd. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $312.22.

Get Our Latest Stock Report on United Therapeutics

Institutional Trading of United Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. International Assets Investment Management LLC increased its position in shares of United Therapeutics by 13,769.2% in the fourth quarter. International Assets Investment Management LLC now owns 9,015 shares of the biotechnology company’s stock valued at $1,982,000 after buying an additional 8,950 shares in the last quarter. DekaBank Deutsche Girozentrale increased its position in shares of United Therapeutics by 54.4% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 94,643 shares of the biotechnology company’s stock valued at $20,617,000 after buying an additional 33,338 shares in the last quarter. Nordea Investment Management AB boosted its stake in shares of United Therapeutics by 155.2% in the fourth quarter. Nordea Investment Management AB now owns 38,698 shares of the biotechnology company’s stock worth $8,427,000 after acquiring an additional 23,532 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of United Therapeutics by 90.3% in the fourth quarter. BNP Paribas Financial Markets now owns 55,481 shares of the biotechnology company’s stock worth $12,200,000 after acquiring an additional 26,325 shares during the last quarter. Finally, Duality Advisers LP boosted its stake in shares of United Therapeutics by 56.1% in the fourth quarter. Duality Advisers LP now owns 15,642 shares of the biotechnology company’s stock worth $3,440,000 after acquiring an additional 5,622 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

About United Therapeutics

(Get Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Featured Articles

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.